Latest

Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ The Pharmacist's Role: How Community Pharmacies in Ireland and the UK Are Adapting as Patients Bypass High-Street Stores for Direct Delivery ◆ GLP-1 Therapeutics and Clinical Research Updates: Brain Reward Mapping, Oral Small Molecules, and Triple-Agonist Horizons ◆ Rinn Pharma & Biopharma Joins NordicPharmaTrain Network to Accelerate European Research & Advanced Manufacturing ◆ Markets Surge as August Opens: $400B Big Pharma Merger Speculation & AstraZeneca Deal Talks Grab Global Headlines ◆ Trump’s September Visit to Ireland: Agenda, Economic Policy Evaluation & U.S.-Irish Trade Implications ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ The Pharmacist's Role: How Community Pharmacies in Ireland and the UK Are Adapting as Patients Bypass High-Street Stores for Direct Delivery ◆ GLP-1 Therapeutics and Clinical Research Updates: Brain Reward Mapping, Oral Small Molecules, and Triple-Agonist Horizons ◆ Rinn Pharma & Biopharma Joins NordicPharmaTrain Network to Accelerate European Research & Advanced Manufacturing ◆ Markets Surge as August Opens: $400B Big Pharma Merger Speculation & AstraZeneca Deal Talks Grab Global Headlines ◆ Trump’s September Visit to Ireland: Agenda, Economic Policy Evaluation & U.S.-Irish Trade Implications ◆

Updated 12 Aug 2026 · ClinicalTrials.gov

Clinical Trials in Changchun

← All China trials

Every active and recruiting clinical study with an investigative site in China — searchable by condition, sponsor, phase and location. Refreshed daily from the ClinicalTrials.gov registry.

3

Recruiting now

7

Active studies

Starting soon

AI-assisted Rare Disease Diagnosis

Rare Disorders, Rare Diseases
Peking Union Medical College Hospital · started 2026-08-01

📍 Beijing · Cangzhou · Changchun · Dongguan · Foshan · Guiyang

NCT07650799 on ClinicalTrials.gov ↗

By invitation

Efficacy and Safety of DS8201 in Metastatic Breast Cancer's Treatment

Breast Cancer Metastatic, Efficacy and Safety
The First Hospital of Jilin University · started 2025-05-25

📍 Changchun

NCT06914661 on ClinicalTrials.gov ↗

Recruiting Phase 2

Qinqiao Yan Shu Granules for the Treatment of Acute Pharyngitis (Exterior Wind-Heat Syndrome) Phase II Clinical Trial

Acute Pharyngitis
Jianmin Pharmaceutical Group Co., LTD. · started 2025-03-26

📍 Harbin · Changsha · Changchun · Jinan · Luzhou · Tianjin

NCT06932328 on ClinicalTrials.gov ↗

Recruiting Phase 3

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Metastatic Non-small Cell Lung Cancer
AstraZeneca · started 2024-10-04

📍 Baoding · Beijing · Bengbu · Changchun · Changsha · Chengdu

NCT06417814 on ClinicalTrials.gov ↗

By invitation Phase 3

A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

Stereotypical Prolonged Seizures
UCB Biopharma SRL · started 2022-02-03

📍 Beijing · Changchun · Chengdu · Chongqing · Fuzhou · Guangzhou

NCT05076617 on ClinicalTrials.gov ↗

Recruiting Phase 3

A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

Myasthenia Gravis
Janssen Research & Development, LLC · started 2021-07-15

📍 Beijing · Changchun · Changsha · Chengdu · Fuzhou · Guangzhou

NCT04951622 on ClinicalTrials.gov ↗

Active Phase 2

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche · started 2020-11-27

📍 Changchun · Guangzhou · Linyi · Nanchang · Shanghai · Tianjin

NCT04576455 on ClinicalTrials.gov ↗

No trials match your search.

Browse by location

Beijing · 65 Guangzhou · 30 Shanghai · 28 Fuzhou · 14 Chengdu · 14 Changsha · 13 Shenzhen · 12 Hangzhou · 11 Tianjin · 10 Wuhan · 9 Chongqing · 8 Changchun · 7

Browse by condition

Breast Cancer · 5 Artificial Intelligence (AI) · 2 Healthy · 2 Aneurysmal Subarachnoid Hemorrhage · 2 Prostate Cancer · 2 Nasopharyngeal Cancinoma (NPC) · 2 Solid Tumors · 2 Healthy Participants · 2 Ischemic Stroke · 2 Wet Age-related Macular Degenerat… · 2 Plaque Psoriasis · 2 Solid Tumor · 2 Colorectal Cancer · 2 Gastric Cancer · 2 Lung Cancer (NSCLC) · 2 Pulmonary Function · 2

Cite this page

Priya Life Science (2026). Clinical Trials in China Tracker. Available at: https://priyalifescience.com/clinical-trials-china/city/changchun (Accessed: 12 August 2026).

Source: ClinicalTrials.gov, U.S. National Library of Medicine — studies listing at least one Chinese site, refreshed daily. Listing here is informational and not medical advice; eligibility is determined by each study team. Patients should discuss participation with their clinician.